Invesco’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-12,936
| Closed | -$20.6K | – | 4033 |
|
|
2024
Q1 | $20.6K | Sell |
12,936
-763
| -6% | -$1.13K | ﹤0.01% | 3837 |
|
|
2023
Q4 | $11.8K | Sell |
13,699
-14,823
| -52% | -$13K | ﹤0.01% | 3815 |
|
|
2023
Q3 | $30.5K | Buy |
28,522
+5,589
| +24% | +$11.6K | ﹤0.01% | 3828 |
|
|
2023
Q2 | $59.4K | Buy |
22,933
+1,695
| +8% | +$6.05K | ﹤0.01% | 3804 |
|
|
2023
Q1 | $86.7K | Buy |
21,238
+1,793
| +9% | +$8.29K | ﹤0.01% | 3714 |
|
|
2022
Q4 | $97.6K | Sell |
19,445
-42,458
| -69% | -$266K | ﹤0.01% | 3832 |
|
|
2022
Q3 | $809K | Buy |
61,903
+7,923
| +15% | +$120K | ﹤0.01% | 3009 |
|
|
2022
Q2 | $693K | Sell |
53,980
-1,258
| -2% | -$17.4K | ﹤0.01% | 3169 |
|
|
2022
Q1 | $842K | Buy |
55,238
+3,313
| +6% | +$51.7K | ﹤0.01% | 3146 |
|
|
2021
Q4 | $920K | Buy |
51,925
+2,730
| +6% | +$52.4K | ﹤0.01% | 3108 |
|
|
2021
Q3 | $1.03M | Buy |
49,195
+34,204
| +228% | +$753K | ﹤0.01% | 3094 |
|
|
2021
Q2 | $296K | Sell |
14,991
-19,775
| -57% | -$463K | ﹤0.01% | 3634 |
|
|
2021
Q1 | $1.01M | Sell |
34,766
-42,412
| -55% | -$1.19M | ﹤0.01% | 3050 |
|
|
2020
Q4 | $2.34M | Buy |
77,178
+33,161
| +75% | +$726K | ﹤0.01% | 2558 |
|
|
2020
Q3 | $700K | Buy |
44,017
+6,185
| +16% | +$113K | ﹤0.01% | 2975 |
|
|
2020
Q2 | $747K | Buy |
+37,832
| New | +$723K | ﹤0.01% | 2942 |
|
Invesco's NGM Position: Q2 2024 in Review
Invesco sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q2 2024, closing a stake of 12,936 shares — an estimated $20.6K sold.
Invesco first reported a position in NGM in Q2 2020 and held it in 16 quarters. The position peaked at $2.34M in Q4 2020. 0 funds tracked by Wall St. Rank hold NGM as of Q2 2024.
- Invesco reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
- Invesco sold 12,936 NGM Biopharmaceuticals, Inc. Common Stock shares in Q2 2024, an estimated $20.6K.
- Invesco first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q2 2020 and held it in 16 quarters.
- Invesco's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $2.34M in Q4 2020.
- 0 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q2 2024.
Based on Invesco's 13F filing for Q2 2024, filed 13 Aug 2024.